Cite
MLA Citation
Carlo Gambacorti‐Passerini et al.. “Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.” American journal of hematology, vol. 97, no. 8, 2022, pp. E296–E298. http://access.bl.uk/ark:/81055/vdc_100159169282.0x000043